Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/royal-society-of-chemistry/the-topology-of-drug-target-interaction-networks-implicit-dependence-jGqlcnfn0i
References (23)
-
Trond Kvernmo, J. Houben, I. Sylte (2008)
Receptor-binding and pharmacokinetic properties of dopaminergic agonists.Current topics in medicinal chemistry, 8 12
-
L. Jensen, Jasmin Saric, P. Bork (2006)
Literature mining for the biologist: from information retrieval to biological discoveryNature Reviews Genetics, 7
-
Sean Ekins, Jordi Mestres, B. Testa (2007)
In silico pharmacology for drug discovery: methods for virtual ligand screening and profilingBritish Journal of Pharmacology, 152
-
M. Cases, Ricard García-Serna, K. Hettne, M. Weeber, J. Lei, S. Boyer, J. Mestres (2005)
Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family.Current topics in medicinal chemistry, 5 8
-
J. Mestres, Elisabet Gregori-Puigjané, S. Valverde, R. Solé (2008)
Data completeness—the Achilles heel of drug-target networksNature Biotechnology, 26
-
M. Cases, J. Mestres (2009)
A chemogenomic approach to drug discovery: focus on cardiovascular diseases.Drug discovery today, 14 9-10
-
Michael Keiser, B. Roth, Blaine Armbruster, P. Ernsberger, J. Irwin, B. Shoichet (2007)
Relating protein pharmacology by ligand chemistryNature Biotechnology, 25
-
B. Roth, D. Sheffler, W. Kroeze (2004)
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophreniaNature Reviews Drug Discovery, 3
-
Alexander Weber, A. Casini, A. Heine, Daniel Kuhn, C. Supuran, A. Scozzafava, G. Klebe (2004)
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.Journal of medicinal chemistry, 47 3
-
M. Hann, A. Leach, G. Harper (2001)
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug DiscoveryJournal of chemical information and computer sciences, 41 3
-
J. Mestres, Lidia Martín-Couce, Elisabet Gregori-Puigjané, M. Cases, S. Boyer (2006)
Ligand-Based Approach to In Silico Pharmacology: Nuclear Receptor ProfilingJournal of chemical information and modeling, 46 6
-
D. Wishart, Craig Knox, Anchi Guo, D. Cheng, S. Shrivastava, D. Tzur, Bijaya Gautam, Murtaza Hassanali (2007)
DrugBank: a knowledgebase for drugs, drug actions and drug targetsNucleic Acids Research, 36
-
N. Savchuk, K. Balakin, S. Tkachenko (2004)
Exploring the chemogenomic knowledge space with annotated chemical libraries.Current opinion in chemical biology, 8 4
-
Tiqing Liu, Yuhmei Lin, Xin Wen, R. Jorissen, M. Gilson (2006)
BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinitiesNucleic Acids Research, 35
-
A. Hopkins, J. Mason, John Overington (2006)
Can we rationally design promiscuous drugs?Current opinion in structural biology, 16 1
-
Elisabet Gregori-Puigjané, J. Mestres (2008)
A ligand-based approach to mining the chemogenomic space of drugs.Combinatorial chemistry & high throughput screening, 11 8
-
G. Paolini, Richard Shapland, W. Hoorn, J. Mason, A. Hopkins (2006)
Global mapping of pharmacological spaceNature Biotechnology, 24
-
M. Vieth, J. Sutherland (2006)
Dependence of molecular properties on proteomic family for marketed oral drugs.Journal of medicinal chemistry, 49 12
-
Elisabet Gregori-Puigjané, J. Mestres (2006)
SHED: Shannon Entropy Descriptors from Topological Feature DistributionsJournal of chemical information and modeling, 46 4
-
B. Roth, E. Lopez, Scott Beischel, R. Westkaemper, Jon Evans (2004)
Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery.Pharmacology & therapeutics, 102 2
-
G. Sud’ina, M. Pushkareva, P. Shephard, Thomas Klein (2008)
Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.Prostaglandins, leukotrienes, and essential fatty acids, 78 2
-
Muhammed Yıldırım, K. Goh, M. Cusick, A. Barabási, M. Vidal (2007)
Drug—target networkNature Biotechnology, 25
-
S. Whitebread, J. Hamon, D. Bojanic, L. Urban (2005)
Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.Drug discovery today, 10 21
- Publisher
- Royal Society of Chemistry
- Copyright
- This journal is © The Royal Society of Chemistry
- ISSN
- 1742-206X
- eISSN
- 1742-2051
- DOI
- 10.1039/b905821b
- pmid
- 19668871
- Publisher site
- See Article on Publisher Site
Abstract
The availability of interaction data between small molecule drugs and protein targets has increased substantially in recent years. Using seven different databases, we were able to assemble a total of 4767 unique interactions between 802 drugs and 480 targets, which means that on average every drug is currently acknowledged to interact with 6 targets. The application of network theory to the analysis of these data reveals an unexpectedly complex picture of drug–target interactions. The results confirm that the topology of drug–target networks depends implicitly on data completeness, drug properties, and target families. The implications for drug discovery are discussed.
Journal
Molecular BioSystems – Royal Society of Chemistry
Published: Aug 11, 2009